{"id":"dolasetron","rwe":[{"pmid":"33630484","year":"2006","title":"Dolasetron.","finding":"","journal":"","studyType":"Clinical Study"},{"pmid":"39899439","year":"2025","title":"CYP2D6 genotype and associated 5-HT(3) receptor antagonist outcomes: A systematic review and meta-analysis.","finding":"","journal":"Clinical and translational science","studyType":"Clinical Study"},{"pmid":"38709223","year":"2024","title":"Results from a Joined Prospective Study to Evaluate the Sensitivity of the In Vivo Dog QT Assay in Line with the ICH E14/S7B Q&A Best Practices.","finding":"","journal":"Clinical pharmacology and therapeutics","studyType":"Clinical Study"},{"pmid":"37624174","year":"2023","title":"Inducing Cytotoxicity in Colon Cancer Cells and Suppressing Cancer Stem Cells by Dolasetron and Ketoprofen through Inhibition of RNA Binding Protein PUM1.","finding":"","journal":"Toxics","studyType":"Clinical Study"},{"pmid":"36852569","year":"2023","title":"The efficacy of 5HT3-receptor antagonists in postoperative nausea and vomiting: the role of pharmacogenetics.","finding":"","journal":"Minerva anestesiologica","studyType":"Clinical Study"}],"tags":[{"label":"Serotonin-3 Receptor Antagonist","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"5-hydroxytryptamine receptor 3A","category":"target"},{"label":"HTR3A","category":"gene"},{"label":"KCNH2","category":"gene"},{"label":"A04AA04","category":"atc"},{"label":"Oral","category":"route"},{"label":"Tablet","category":"form"},{"label":"Off-Patent","category":"patent"},{"label":"Active","category":"status"},{"label":"Post-Operative Nausea and Vomiting","category":"indication"},{"label":"Prevention of Post-Operative Nausea and Vomiting","category":"indication"},{"label":"Validus Pharms","category":"company"},{"label":"Approved 1990s","category":"decade"},{"label":"Antiemetics","category":"pharmacology"},{"label":"Central Nervous System Agents","category":"pharmacology"},{"label":"Gastrointestinal Agents","category":"pharmacology"},{"label":"Neurotransmitter Agents","category":"pharmacology"},{"label":"Peripheral Nervous System Agents","category":"pharmacology"},{"label":"Serotonin 5-HT3 Receptor Antagonists","category":"pharmacology"},{"label":"Serotonin Agents","category":"pharmacology"},{"label":"Serotonin Antagonists","category":"pharmacology"}],"phase":"marketed","safety":{"safetySignals":[{"llr":230.412,"date":"","count":241,"signal":"Death","source":"DrugCentral FAERS","actionTaken":"Reported 241 times (LLR=230)"},{"llr":64.36,"date":"","count":71,"signal":"Disease progression","source":"DrugCentral FAERS","actionTaken":"Reported 71 times (LLR=64)"},{"llr":61.275,"date":"","count":5,"signal":"Drug ineffective","source":"DrugCentral FAERS","actionTaken":"Reported 5 times (LLR=61)"},{"llr":53.72,"date":"","count":158,"signal":"Nausea","source":"DrugCentral FAERS","actionTaken":"Reported 158 times (LLR=54)"},{"llr":36.396,"date":"","count":141,"signal":"Off label use","source":"DrugCentral FAERS","actionTaken":"Reported 141 times (LLR=36)"},{"llr":34.732,"date":"","count":143,"signal":"Fatigue","source":"DrugCentral FAERS","actionTaken":"Reported 143 times (LLR=35)"},{"llr":34.581,"date":"","count":89,"signal":"Asthenia","source":"DrugCentral FAERS","actionTaken":"Reported 89 times (LLR=35)"},{"llr":33.428,"date":"","count":34,"signal":"Flushing","source":"DrugCentral FAERS","actionTaken":"Reported 34 times (LLR=33)"},{"llr":29.773,"date":"","count":40,"signal":"Pleural effusion","source":"DrugCentral FAERS","actionTaken":"Reported 40 times (LLR=30)"},{"llr":29.56,"date":"","count":100,"signal":"Vomiting","source":"DrugCentral FAERS","actionTaken":"Reported 100 times (LLR=30)"},{"llr":24.64,"date":"","count":12,"signal":"Dermatitis acneiform","source":"DrugCentral FAERS","actionTaken":"Reported 12 times (LLR=25)"},{"llr":22.769,"date":"","count":38,"signal":"Chills","source":"DrugCentral FAERS","actionTaken":"Reported 38 times (LLR=23)"},{"llr":22.198,"date":"","count":54,"signal":"Constipation","source":"DrugCentral FAERS","actionTaken":"Reported 54 times (LLR=22)"},{"llr":22.062,"date":"","count":38,"signal":"Neuropathy peripheral","source":"DrugCentral FAERS","actionTaken":"Reported 38 times (LLR=22)"}],"drugInteractions":[{"url":"/drug/high-risk-qt-prolonging-agents","drug":"High Risk QT Prolonging Agents","action":"Avoid combination","effect":"Moderate Risk QTc-Prolonging Agents may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents","source":"DrugCentral","drugSlug":"high-risk-qt-prolonging-agents"},{"url":"/drug/flecainide","drug":"flecainide","action":"Monitor closely","effect":"May interact with Dolasetron Mesylate, Flecainide","source":"DrugCentral","drugSlug":"flecainide"},{"url":"/drug/quinidine","drug":"quinidine","action":"Monitor closely","effect":"May interact with Dolasetron Mesylate, Quinidine","source":"DrugCentral","drugSlug":"quinidine"},{"url":"/drug/verapamil","drug":"verapamil","action":"Monitor closely","effect":"May interact with Dolasetron Mesylate, Verapamil","source":"DrugCentral","drugSlug":"verapamil"},{"url":"/drug/ziprasidone","drug":"ziprasidone","action":"Avoid combination","effect":"May interact with Dolasetron Mesylate, Ziprasidone","source":"DrugCentral","drugSlug":"ziprasidone"}],"commonSideEffects":[{"effect":"Headache","drugRate":"20.4%","severity":"common","organSystem":""},{"effect":"Bradycardia","drugRate":"4.6%","severity":"common","organSystem":""},{"effect":"Fatigue","drugRate":"4.1%","severity":"common","organSystem":""},{"effect":"Diarrhea","drugRate":"3.7%","severity":"common","organSystem":""},{"effect":"Pain","drugRate":"3.1%","severity":"common","organSystem":""},{"effect":"Dyspepsia","drugRate":"2.6%","severity":"common","organSystem":""},{"effect":"Tachycardia","drugRate":"2.8%","severity":"common","organSystem":""},{"effect":"Chills/Shivering","drugRate":"1.7%","severity":"common","organSystem":""},{"effect":"Dizziness","drugRate":"2.2%","severity":"common","organSystem":""},{"effect":"Rash","drugRate":"<2%","severity":"common","organSystem":""},{"effect":"Increased sweating","drugRate":"<2%","severity":"common","organSystem":""},{"effect":"Constipation","drugRate":"<2%","severity":"common","organSystem":""},{"effect":"Abdominal pain","drugRate":"<2%","severity":"common","organSystem":""},{"effect":"Anorexia","drugRate":"<2%","severity":"common","organSystem":""},{"effect":"Taste perversion","drugRate":"<2%","severity":"common","organSystem":""},{"effect":"Abnormal vision","drugRate":"<2%","severity":"common","organSystem":""},{"effect":"Myalgia","drugRate":"<2%","severity":"common","organSystem":""},{"effect":"Arthralgia","drugRate":"<2%","severity":"common","organSystem":""},{"effect":"Flushing","drugRate":"<2%","severity":"common","organSystem":""},{"effect":"Vertigo","drugRate":"<2%","severity":"common","organSystem":""}],"contraindications":["Atrioventricular Conduction Defect","Bradycardia","Chemotherapy-induced nausea and vomiting","Chronic heart failure","Congenital long QT syndrome","Doxorubicin Induced Cardiomyopathy","Heart block","Hypokalemia","Hypomagnesemia","Kidney disease","Prolonged QT interval","Torsades de pointes"],"specialPopulations":{"Pregnancy":"There are, however, no adequate and well-controlled studies in pregnant women. Be cautious.","Geriatric use":"Elderly patients are at particular risk for prolongation of the PR, QRS, and QT interval; therefore, caution should be exercised and ECG monitoring should be performed when using ANZEMET in this population."},"seriousAdverseEvents":[{"effect":"Ventricular fibrillation cardiac arrest","drugRate":"<1%","severity":"serious"},{"effect":"Wide complex tachycardia/ventricular tachycardia","drugRate":"<1%","severity":"serious"},{"effect":"Severe hypotension","drugRate":"<1%","severity":"serious"},{"effect":"Severe bradycardia","drugRate":"<1%","severity":"serious"},{"effect":"Syncope","drugRate":"<1%","severity":"serious"},{"effect":"Anaphylactic reaction","drugRate":"<1%","severity":"serious"},{"effect":"Pancreatitis","drugRate":"<1%","severity":"serious"},{"effect":"Acute renal failure","drugRate":"<1%","severity":"serious"},{"effect":"Bronchospasm","drugRate":"<1%","severity":"serious"},{"effect":"Myocardial ischemia","drugRate":"<1%","severity":"serious"}]},"trials":[],"aliases":[],"company":"Validus Pharms","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=DOLASETRON","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:18:43.830310+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T03:18:49.178714+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=DOLASETRON","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T03:18:49.574007+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Serotonin 3a (5-HT3a) receptor antagonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:18:50.644365+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2368924/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:18:50.293971+00:00"}},"allNames":"anzemet","offLabel":[],"synonyms":["MDL 73,147EF","dolasetron methanesulfonate hydrate","dolasetron mesylate hydrate","anzemet hydrate","anzemet","dolasetron","anemet","dolasetron mesylate","dolasetron mesilate"],"timeline":[{"date":"1997-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from SANOFI AVENTIS US to Validus Pharms"},{"date":"1997-09-11","type":"positive","source":"DrugCentral","milestone":"FDA approval (Sanofi Aventis Us)"}],"aiSummary":"Anzemet (Dolasetron) is a serotonin-3 receptor antagonist developed by Sanofi Aventis US and currently owned by Validus Pharms. It targets the 5-hydroxytryptamine receptor 3A and is a small molecule modality. FDA-approved in 1997 for post-operative nausea and vomiting, Anzemet is a non-generic, off-patent medication with no active Orange Book patents. Key safety considerations include its short half-life of 0.13 hours and 75% bioavailability. Anzemet is a valuable option for preventing post-operative nausea and vomiting.","approvals":[{"date":"1997-09-11","orphan":false,"company":"SANOFI AVENTIS US","regulator":"FDA"}],"brandName":"Anzemet","ecosystem":[{"indication":"Post-Operative Nausea and Vomiting","otherDrugs":[{"name":"droperidol","slug":"droperidol","company":"Akorn Inc"},{"name":"granisetron","slug":"granisetron","company":"Roche"}],"globalPrevalence":null},{"indication":"Prevention of Post-Operative Nausea and Vomiting","otherDrugs":[{"name":"aprepitant","slug":"aprepitant","company":"Merck"},{"name":"estrone","slug":"estrone","company":"Watson Labs"},{"name":"granisetron","slug":"granisetron","company":"Roche"},{"name":"metoclopramide","slug":"metoclopramide","company":"Baxter Hlthcare Corp"}],"globalPrevalence":null}],"mechanism":{"target":"5-hydroxytryptamine receptor 3A","novelty":"Follow-on","targets":[{"gene":"HTR3A","source":"DrugCentral","target":"5-hydroxytryptamine receptor 3A","protein":"5-hydroxytryptamine receptor 3A"},{"gene":"KCNH2","source":"DrugCentral","target":"Potassium voltage-gated channel subfamily H member 2","protein":"Potassium voltage-gated channel subfamily H member 2"}],"moaClass":"Serotonin 3 Receptor Antagonists","modality":"Small Molecule","drugClass":"Serotonin-3 Receptor Antagonist","explanation":"","oneSentence":"","technicalDetail":"Anzemet (Dolasetron) is a selective 5-HT3 receptor antagonist that competes with serotonin for binding sites on the 5-HT3 receptor, thereby inhibiting the serotonin-mediated activation of the vomiting reflex."},"commercial":{"launchDate":"1997","_launchSource":"DrugCentral (FDA 1997-09-11, SANOFI AVENTIS US)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/3931","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=DOLASETRON","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=DOLASETRON","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T10:49:00.408349","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:18:52.103167+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"ondansetron","drugSlug":"ondansetron","fdaApproval":"1991-01-04","patentExpiry":"Nov 23, 2029","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"granisetron","drugSlug":"granisetron","fdaApproval":"1993-12-29","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"palonosetron","drugSlug":"palonosetron","fdaApproval":"2003-07-25","genericCount":16,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"genericName":"dolasetron","indications":{"approved":[{"name":"Post-Operative Nausea and Vomiting","source":"DrugCentral","snomedId":1488000,"regulator":"FDA"},{"name":"Prevention of Post-Operative Nausea and Vomiting","source":"DrugCentral","snomedId":"","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"currentOwner":"Validus Pharms","drugCategory":"active","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"ondansetron","brandName":"ondansetron","genericName":"ondansetron","approvalYear":"1991","relationship":"same-class"},{"drugId":"granisetron","brandName":"granisetron","genericName":"granisetron","approvalYear":"1993","relationship":"same-class"},{"drugId":"palonosetron","brandName":"palonosetron","genericName":"palonosetron","approvalYear":"2003","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT04817189","phase":"PHASE4","title":"Oral Akynzeo® vs Standard of Care in Preventing CINV in High-risk MEC Patients (MyRisk)","status":"COMPLETED","sponsor":"Helsinn Healthcare SA","startDate":"2021-02-01","conditions":["Chemotherapy-induced Nausea and Vomiting"],"enrollment":414,"completionDate":"2024-07-02"},{"nctId":"NCT00820326","phase":"PHASE3","title":"Efficacy of Dolasetron in Patients With Fibromyalgia","status":"COMPLETED","sponsor":"University Hospital, Limoges","startDate":"2004-03","conditions":["Fibromyalgia"],"enrollment":60,"completionDate":"2008-06"},{"nctId":"NCT06756022","phase":"","title":"Dolasetron for the Prevention of CINV in Children With Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"Anhui Provincial Children's Hospital","startDate":"2024-11-21","conditions":["Chemotherapy Induced Nausea and Vomiting"],"enrollment":500,"completionDate":"2025-12-31"},{"nctId":"NCT06593782","phase":"PHASE2","title":"Evaluating the Efficacy and Safety of HSK21542 Injection in Chemotherapy-induced Nausea and Vomiting","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital of Wenzhou Medical University","startDate":"2024-09-16","conditions":["Nausea and Vomiting, Chemotherapy-Induced"],"enrollment":180,"completionDate":"2025-09-01"},{"nctId":"NCT03805945","phase":"PHASE4","title":"Effect of Dexmedetomidine on Parturient Undergoing Elective Cesarean Section.","status":"COMPLETED","sponsor":"The Affiliated Hospital of Xuzhou Medical University","startDate":"2019-06-01","conditions":["Cesarean Section"],"enrollment":160,"completionDate":"2019-12-02"},{"nctId":"NCT02625181","phase":"NA","title":"Real-time Decision Support for Postoperative Nausea and Vomiting (PONV) Prophylaxis","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2016-07","conditions":["Postoperative Nausea and Vomiting"],"enrollment":27034,"completionDate":"2017-11-30"},{"nctId":"NCT01636947","phase":"PHASE4","title":"A Korean Study of Efficacy and Safety of Aprepitant-based Triple Regimen for the Prevention of Chemotherapy-Induced Nausea and Vomiting in the First Cycle of Moderately Emetogenic Chemotherapy (Non-doxorubicin Hydrochloride [Adriamycin] and Cyclophosphamide Regimens) (MK-0869-225) (KMEC)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-12-12","conditions":["Nausea","Vomiting"],"enrollment":494,"completionDate":"2014-08-04"},{"nctId":"NCT01594749","phase":"PHASE3","title":"Efficacy and Safety of Fosaprepitant Dimeglumine in Preventing Chemotherapy-Induced Nausea and Vomiting (MK-0517-031)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-09-24","conditions":["Chemotherapy-Induced Nausea and Vomiting (CINV)"],"enrollment":1015,"completionDate":"2014-11-03"},{"nctId":"NCT01364805","phase":"PHASE1","title":"New Treatment Option for Pancreatic Cancer","status":"COMPLETED","sponsor":"Jeanne Drisko, MD, CNS, FACN","startDate":"2011-04","conditions":["Pancreatic Cancer"],"enrollment":14,"completionDate":"2015-10"},{"nctId":"NCT00511823","phase":"PHASE1","title":"The Pharmacokinetic Interaction Between Oral Casopitant and Oral Dolasetron, Granisetron or Rosiglitazone in Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-07-23","conditions":["Nausea and Vomiting, Chemotherapy-Induced"],"enrollment":16,"completionDate":"2007-09-21"},{"nctId":"NCT02550119","phase":"NA","title":"Dolasetron Mesylate and Dexamethasone With or Without Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Oxaliplatin-Containing Chemotherapy for Gastrointestinal Malignancy","status":"TERMINATED","sponsor":"University of Southern California","startDate":"2006-04-19","conditions":["Malignant Digestive System Neoplasm","Nausea and Vomiting"],"enrollment":19,"completionDate":"2010-04-01"},{"nctId":"NCT00020657","phase":"PHASE3","title":"Comparison of Antiemetic Drugs in Preventing Delayed Nausea After Chemotherapy in Patients With Cancer","status":"COMPLETED","sponsor":"Gary Morrow","startDate":"2001-07","conditions":["Nausea and Vomiting","Unspecified Adult Solid Tumor, Protocol Specific"],"enrollment":0,"completionDate":"2004-10"},{"nctId":"NCT00003817","phase":"PHASE2","title":"Acupressure and Acustimulation Wrist Bands for the Prevention of Nausea and Vomiting Caused by Chemotherapy","status":"COMPLETED","sponsor":"Gary Morrow","startDate":"1999-10","conditions":["Nausea and Vomiting","Unspecified Adult Solid Tumor, Protocol Specific"],"enrollment":700,"completionDate":"2001-07"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Oral","formulation":"Tablet","formulations":[{"form":"TABLET, FILM COATED","route":"ORAL","productName":"ANZEMET"}]},"_patentsChecked":true,"crossReferences":{"MMSL":"11370","NDDF":"006880","UNII":"82WI2L7Q6E","CHEBI":"CHEBI:4682","VANDF":"4021059","INN_ID":"6780","RXNORM":"215357","UMLSCUI":"C0209210","chemblId":"CHEMBL2368924","ChEMBL_ID":"CHEMBL2368925","KEGG_DRUG":"D00725","DRUGBANK_ID":"DB00757","PUBCHEM_CID":"3033818","SNOMEDCT_US":"108421009","SECONDARY_CAS_RN":"878143-33-0","MESH_SUPPLEMENTAL_RECORD_UI":"C060344"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"1997-","companyName":"Sanofi","relationship":"Original Developer"},{"period":"present","companyName":"Validus Pharms","relationship":"Current Owner"}],"pharmacokinetics":{"source":"DrugCentral","halfLife":"0.13 hours","clearance":"180.0 mL/min/kg","bioavailability":"75%","fractionUnbound":"0.49%","volumeOfDistribution":"2.0 L/kg"},"publicationCount":279,"therapeuticAreas":["Other"],"atcClassification":{"source":"DrugCentral","atcCode":"A04AA04","allCodes":["A04AA04"]},"biosimilarFilings":[],"originalDeveloper":"Sanofi Aventis Us","recentPublications":[{"date":"2006","pmid":"33630484","title":"Dolasetron.","journal":""},{"date":"2025 Feb","pmid":"39899439","title":"CYP2D6 genotype and associated 5-HT(3) receptor antagonist outcomes: A systematic review and meta-analysis.","journal":"Clinical and translational science"},{"date":"2024 Jul","pmid":"38709223","title":"Results from a Joined Prospective Study to Evaluate the Sensitivity of the In Vivo Dog QT Assay in Line with the ICH E14/S7B Q&A Best Practices.","journal":"Clinical pharmacology and therapeutics"},{"date":"2023 Aug 3","pmid":"37624174","title":"Inducing Cytotoxicity in Colon Cancer Cells and Suppressing Cancer Stem Cells by Dolasetron and Ketoprofen through Inhibition of RNA Binding Protein PUM1.","journal":"Toxics"},{"date":"2023 Jun","pmid":"36852569","title":"The efficacy of 5HT3-receptor antagonists in postoperative nausea and vomiting: the role of pharmacogenetics.","journal":"Minerva anestesiologica"}],"companionDiagnostics":[],"genericManufacturers":0,"_genericFilersChecked":true,"genericManufacturerList":[],"status":"approved","companyName":"Validus Pharms","companyId":"validus-pharms","modality":"Small molecule","firstApprovalDate":"1997","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1997-09-11T00:00:00.000Z","mah":"SANOFI AVENTIS US","brand_name_local":null,"application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:18:52.103167+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}